Loading
A phase 1/2 trial of Trastuzumab rezetecan, Bevacizumab, SHR-8068 in cervical cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer is a phase 1/2 interventional study registered as NCT06859775 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 100 participants planned, started 2025-04-25 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A1811, Adebelimab injection, Bevacizumab injection, SHR-8068, Cisplatin injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab rezetecan, Recurrent or metastatic cervical cancer, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares SHR-8068, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares SHR-8068, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Cervical cancer.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).